Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Telik
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Clinical diagnosis of non-small cell lung cancer

• Non-small cell lung cancer that is not curable with surgery, radiation, or combined modality chemoradiation

• Failed two prior chemotherapy regimens which must have included platinum

• Measurable disease

Exclusion Criteria:

• Treatment with more than two prior chemotherapy regimens

• History of bone marrow transplantation or stem cell support

• Pregnant or lactating women

• Known history of prior gefitinib therapy

• Known history of prior TLK286 therapy